Emerging Therapies in Non–Clear Cell Renal Cell Carcinoma
Robert J. Motzer, MD, concludes the program with insights on promising treatment options for patients with non–clear cell renal cell carcinoma.
Updates from ASCO 2023 for Non–Clear Cell RCC
A medical oncologist reviews recent data updates from the 2023 ASCO Annual Meeting for non–clear cell renal cell carcinoma.
RCC Histologies: Clear Cell vs Non–Clear Cell
Clinical insights from a leader in kidney cancer research on the differences between clear cell and non–clear cell renal cell carcinoma.
Future Outlook of Treatment for Clear Cell RCC
Robert J. Motzer, MD, discusses unmet needs and looks to the future of treatment for patients with clear cell renal cell carcinoma.
Safety Profiles of Treatment Regimens for Clear Cell RCC
Expert perspectives on how adverse events differ among the available clear cell renal cell carcinoma treatment options.
Strategies for Sequencing Therapies in Renal Cell Carcinoma
A key opinion leader in the field of renal cell carcinoma offers clinical insight on treatment sequencing strategies.
Second-Line Treatment Options for Patients With Clear Cell RCC
A comprehensive review of second-line treatment options for patients with clear cell renal cell carcinoma.
Clear Cell RCC: Strategies for Selecting Appropriate Frontline Treatment
Robert J. Motzer, MD, provides insights on factors that influence treatment decisions for patients with clear cell renal cell carcinoma.
Clinical Trial Data Updates in Advanced Renal Cell Carcinoma
Continuing discussion on advanced renal cell carcinoma, Robert J. Motzer, MD, reviews recent clinical trial data presented at ASCO 2023 and KCRS 2023.
Recent Data on Lenvatinib Plus Pembrolizumab in Advanced RCC
An expert medical oncologist reviews recent data updates on lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
CLEAR Trial: Lenvatinib Plus Pembrolizumab in Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, provides an overview of the CLEAR trial investigating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Unmet Needs and Future Outlook in aRCC Treatment
The panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.
Novel Triplet Combination Regimens in Frontline RCC
Ongoing studies assessing triplet regimens in frontline advanced RCC and their influence on treatment decisions are discussed, including efficacy outcomes.
Novel Doublet Combination Regimens in Frontline Advanced RCC
Panelists provide insight on ongoing studies evaluating doublet combinations in frontline advanced RCC.
Insights from the Community: Optimizing Care for Patients with aRCC
Expert oncologists share experiences and insights on key treatment protocols for patients with aRCC, including perspectives from community oncologists.
Dosing and Tolerability of First-line Treatment Options in Clinical Practice
The panel engages in a discussion on lenvatinib dosing in clinical practice, addressing dose reductions, their impact on treatment effectiveness, and real-world tolerability.
4-Year Follow-Up Results of Lenvatinib Plus Pembrolizumab in Frontline aRCC
Panelists analyze the 4-year follow-up results of the CLEAR study, covering study design, efficacy, safety, and clinical implications.
First-Line Combination Options in Advanced Renal Cell Carcinoma
Discussion centered around available first-line combination options for patients with aRCC as well as factors influencing treatment choice.
Overview of Advanced Renal Cell Carcinoma
An overview of advanced Renal Cell Carcinoma (aRCC), including its prevalence, patient presentation, classification, and treatment criteria.
Promising Studies for the Future of Frontline mRCC
Toni Choueiri, MD, closes with promising new studies that will impact metastatic clear-cell renal cell carcinoma therapeutics in the years to come.
Using TKI/IO Combinations in Patients With mRCC
Both nivolumab + ipilimumab and lenvatinib + pembrolizumab TKI/IO combinations are discussed, with patient selection and appropriate use being the focus.
Dosing Strategies for Maximum Efficacy With Len + Pembro
Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.
Safety Profile of Len + Pembro From CLEAR in mRCC
Hutson and Choueiri compare the safety profiles of lenvatinib + pembrolizumab against other TKI/IO combinations for patients with metastatic clear-cell renal cell carcinoma.
CLEAR Trial: Len + Pembro or Everolimus vs Sunitinib
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, talk about the phase 3 CLEAR trial at length, including each of the 3 arms of the trial and key data.
FDA-Approved TKI/IO Combinations in mRCC
Hutson and Choueiri elaborate on the FDA-approved TKI + ICI combinations and their data from the following trials: KEYNOTE-146, JAVELIN Renal 101, and CheckMate-9ER.
Combining VEGF-TKIs + ICIs in mRCC
Toni Choueiri, MD, focuses on combining VEGF-tyrosine kinase inhibitors with immune checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.
Prevalence of Actionable Biomarkers in Clear-Cell RCC
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, discuss the available biomarkers, predictive biomarkers, and clinical predictors that are currently used in metastatic clear-cell renal cell carcinoma, as well as risk status.
Frontline Treatment of Advanced Renal Cell Carcinoma
The panelists discuss frontline treatment for renal cell carcinoma, highlighting TKIs targeting VEGFR and the mechanisms of action for currently approved therapeutics.
Examining TKI Combinations in Advanced RCC
A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
Nivolumab for the Treatment of mRCC
Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses nivolumab for the treatment of metastatic renal cell carcinoma.
2 Commerce Drive Cranbury, NJ 08512